J&J Eyes a $20 Billion 'Hip Replacement,' Shopping DePuy Synthes to Apollo

By Stocks News   |   2 months ago   |   Stock Market News
J&J Eyes a $20 Billion 'Hip Replacement,' Shopping DePuy Synthes to Apollo

Déjà Kenvue, anyone? 

Well friends, your grandma’s knee replacement may just be getting its private equity on. Johnson & Johnson is in talks to sell DePuy Synthes, its hips-knees-and-assorted-titanium unit, to Apollo Global Management for close to $20 billion, per Bloomberg… and the two sides have apparently been sneaky linking long enough that a deal could land within weeks. 

Nothing is signed, of course. Talks could still collapse, but word on the street is that other private equity vultures shops are circling the same target. Friendly reminder on how we got here, J&J announced plans last October to separate the unit, and Wolk It Off (read: CFO Joe Wolk) has spent every earnings call since promising to weigh "all separation options that create shareholder value" on a mid-2027 timeline. The same guy called the business "a steady grower,  but not a shower outperforming" and told the Financial Times that the next generation of orthopedic robotics is "beyond our scope and probably in better hands somewhere else." Woof.

Which brings us to DePuy Synthes, which put up a blistering $9.3 billion in sales last year, and J&J says the standalone version would be the world's largest orthopedics company on day one, which, per the guys selling it. The rest of the family tells you why it's on the block anyway: Innovative Medicine powered J&J's $25.31 billion second quarter (up 6.6%), while MedTech, where DePuy lives, tacked on 4.5%. In other words, DePuy is the redheaded stepchild of the portfolio… profitable, enormous, and still getting boxed up for growing a couple points slower than the pharma golden child (the audacity).

Keep in mind, J&J has run this play before, It kicked its consumer-health kid out of the house in 2023 (read: Kenvue, the Tylenol and Band-Aid people), and Kimberly-Clark just agreed to scoop that same kid up for north of $40 billion, which, not bad.

As for Apollo, the firm is sitting on dry powder for exactly this kind of thing… it has already raised $12 billion toward a new $25 billion flagship fund, and DePuy would still be its biggest healthcare bet ever. And yes, the standard PE exit involves picking all the meat off the bones, which lands a little differently when bones are the product. Oh, and per the WSJ, J&J could still spin the unit off as a public company instead… but a $20 billion bird in the hand tends to beat a 2027 ticker in the bush.

Regardless, the takeaway here is that J&J spent a year calling this a silent auction separation process, and somebody is finally playing just the tip with a big enough check. And this one just so happens to be $20 big ones. Place your bets accordingly, friends. Until next time… 

At the time of publishing, Stocks.News holds positions in Johnson & Johnson as mentioned in the article. 

 

Did you find this insightful?

Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer